BACKGROUND Allogeneic hematopoietic cell transplantation is the main curative therapy for patients with chronic myeloid leukemia who do not respond to tyrosine kinase inhibitors. It has been proposed that non-human leukocyte antigen gene polymorphisms influence outcome after hematopoietic cell transplantation and could be used alongside traditional patient-donor and transplant characteristics t...

BACKGROUND Chronic myeloid leukemia is successfully managed by imatinib therapy, but the question remains whether treatment must be administered indefinitely. Imatinib discontinuation trials have led to two distinct outcomes: about 60% of patients experienced disease relapse within 6 months of treatment cessation, while the remaining 40% remained disease-free throughout the duration of follow-u...

BACKGROUND Published criteria defining the accelerated phase in chronic myeloid leukemia are heterogeneous and little is known about predictors of poor outcome. METHODS This is a retrospective study of 139 subjects in the accelerated phase of chronic myeloid leukemia treated with imatinib at a single center in Brazil. The objective was to identify risk factors for survival, major cytogenetic ...

Nonhuman primate antisera defining leukemia-associ ated and normal Tand B-lymphocyte-associated anti gens were used to characterize serologically the cells from acute myelomonocytic leukemia (AMML) and chronic myelogenous leukemia patients in blast crisis (CML-BC). Earlier studies demonstrated that nonhuman primate an tisera to chronic lymphocytic leukemia, acute myelogen ous leukemia, and chro...

We compared the incidence of submicroscopic deletions accompanying balanced translocations using interphase fluorescence in situ hybridization (FISH) in 245 patients with chronic myeloid leukemia (CML), 79 patients with acute lymphoblastic leukemia (ALL) and BCR-ABL (n=70) or MLL rearrangements (n=29), and 412 patients with acute myeloid leukemia (AML) with CBFB-MYH11 (n=122), PML-RARalpha (n=1...

Disease Myelodysplastic syndrome (21 cases), Acute Myeloid Leukemia (5 cases), Chronic Myelomonocytic Leukemia (1 case). Phenotype/cell stem origin Thrombopenia (90%) with anemia (60%). Dysplastic changes in bone marrow: dyserythropoeisis associated with dysgranulopoieisis and/or dysmegakaryocytopoeisis. Epidemiology The frequency of ider(20q) is estimated at 0.49% in myelodysplastic syndrome a...

Journal of Leukemia is an open access journal organized by OMICS International, a self-supporting organization. The journal includes a wide range of fields in all areas of hematooncology, mainly related to multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, pediatric leukemia and other relevant fiel...

Background: VEGF play a significant role in the pathogenesis of chronic myeloid leukemia. Aims & Objective: (1) Assess the pathophysiological role of VEGF in patients with chronic myeloid leukemia (CML). (2) Study the effect of Hydroxyurea and Imatinib on serum VEGF level. Material and Methods: A total of 40 cases of chronic myeloid leukemia (CML) and 20 age and sex matched healthy controls wer...

The presence of la-antigens and their relationship to the inhibitory effect of prostaglandin E on the proliferation of human CFU-GM was studied in animals and patients with chronic myeloid leukemia. Consistent reduction of normal colony formation to approximately 50% of baseline levels was observed using a monoclonal anti-human la antibody in a complement-dependent cytotoxicity assay titrated o...

BACKGROUND A specific chromosomal abnormality, the Philadelphia chromosome, is present in 90 - 95% of patients with chronic myeloid leukemia. The aberration results from a reciprocal translocation of chromosomes 9 and 22, creating a BCR-ABL fusion gene. There are two major forms of the BCR-ABL fusion gene, involving ABL exon 2, but including different exons of BCR gene. The transcript b2a2 or b...